Inactive Instrument

Beigene Ltd Share Price Hong Kong S.E.

Equities

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E.
- HKD - Intraday chart for Beigene Ltd

Financials

Sales 2024 * 3.19B 24.91B 254B Sales 2025 * 3.99B 31.2B 319B Capitalization 16.85B 132B 1,345B
Net income 2024 * -950M -7.42B -75.84B Net income 2025 * -317M -2.48B -25.31B EV / Sales 2024 * 4.79 x
Net cash position 2024 * 1.59B 12.39B 127B Net cash position 2025 * 1.02B 7.98B 81.49B EV / Sales 2025 * 3.96 x
P/E ratio 2024 *
-17.4 x
P/E ratio 2025 *
-44.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company